Group 1: Investment Strategy and Market Positioning - Junlian Capital successfully invested in leading companies in the AGI and surgical robotics sectors, with a long-term investment strategy that includes nine rounds of funding for Zhipu and three for Jingfeng Medical [1][3][5] - The AGI market in China is projected to exceed 1 trillion yuan by 2030, with a compound annual growth rate (CAGR) of over 63% [4] - Junlian Capital has established a comprehensive investment landscape in the AI sector, focusing on three main areas: vertical applications of AI, foundational large models, and AI infrastructure [4] Group 2: Company Highlights - Zhipu, founded in 2019, has developed the GLM series of large models, achieving significant milestones such as surpassing 100 billion parameters and ranking first in domestic evaluations [3][4] - Jingfeng Medical, established in 2017, is a leading surgical robotics company in China, recognized for its innovative technology and multiple regulatory approvals for various surgical robots [6][7] - Both companies' listings mark a significant achievement for the Social Security Fund's Zhongguancun Special Fund, highlighting Junlian Capital's investment acumen in hard technology [7]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. is set to become the first domestic surgical robot company listed on the Hong Kong Stock Exchange, having passed the listing hearing on December 21, 2025 [2] Group 1: IPO Details - The company plans to issue up to 31.88 million new shares, with 49 shareholders converting 296 million shares into H-shares for circulation [3] - Joint sponsors for the IPO include Morgan Stanley and GF Securities [3] Group 2: Company Overview - Established in 2017, Precision Medical is the first in China and the second globally to have listing qualifications for multi-port, single-port, and natural orifice surgical robots [3] - The company focuses on the R&D, production, and sales of surgical robots and related instruments, covering various minimally invasive surgical needs across multiple departments [3] Group 3: Technological and Market Position - As of May 2025, the company holds over 800 global patents and patent applications, achieving self-controlled core technologies that break the long-standing overseas monopoly [3] - The products have been adopted in over 220 top-tier hospitals across 30 provinces in China, including renowned institutions like Peking University Third Hospital and Zhejiang University First Hospital [3] - Overseas revenue accounts for 40.60%, establishing a dual growth engine from domestic and international markets [3] Group 4: Financial Performance - The company demonstrates stable profitability, with gross margins of 59.30%, 61.30%, and 62.80% for the years 2023 to the first half of 2025, showing a steady upward trend [4] - In the first half of 2025, revenue reached 149 million yuan, indicating strong growth performance [4]